Prognostic and predictive markers of treatment response in autoimmune disease
The group's research activity is currently focused and will be focused for the next 5 years on:
1.- Immune-mediated inflammatory diseases (IMID), particularly psoriasis. The main lines of research are:
- a.- Immunoregulatory molecules as markers that predict the response to biological therapies and the severity of the disease in IMIDs. This is a group of diseases with inflammation as the main pathogenic mechanism. Their long-term impact has been mitigated by the implementation of biological therapies. Despite growing knowledge of the aetiopathogenesis of these diseases, and the remarkable improvement in their management due to biological therapy, we lack markers of disease severity or markers to predict whether patients will be resistant to treatment. We are looking for new biomarkers to predict the severity of IMIDs and their response to biologics.
- b.- Gene expression profile in patients with moderate to severe psoriasis.
- c.- Epigenetic biomarkers as predictors of the therapeutic response to biological drugs in psoriasis.
- d.- Immunoregulatory molecules and their therapeutic potential. We are researching the possible role of GADD45, ICOSL, TSP-1 and galectins in the immunopathogenesis of psoriasis, and the possibility of finding new therapeutic targets for this disease.
- e.- Survival analysis of conventional and biological systemic therapies in psoriasis.
- f.- Factors associated with treatment with biological therapies or classic systemic therapy in moderate to severe psoriasis.
- g.- Study of paradoxical psoriasiform reactions with morphological changes induced by biological therapy in psoriasis. Determination of prevalence, clinical and histopathological characteristics, possible triggers or associated factors. Assessment of therapeutic management.
- h.- Identification of copy number variants associated with the risk of developing psoriasis and arthritic psoriasis using a complete genome analysis approach.
- i.- Study of optimisation strategies (dose reduction, increased interval administration) in the treatment of moderate to severe psoriasis with systemic agents.
2.- Eczematous dermatitis. Study of the prevalence of allergens as responsible for allergic contact dermatitis in the Spanish population.
3.-Connective tissue diseases. Determination of the association between specific myositis autoantibodies and myosistis-associated autoantibodies and clinical amyopathic dermatomyositis.
Team members
|
Esteban Daudén Tello Hospital Universitario La Princesa |
Other team members. Hospital Universitario La Princesa:
|
Group leader:Daudén Tello, Esteban. Immunoregulatory molecules as biomarkers predicting response to biological therapies and disease severity in immune-mediated inflammatory disorders. BIOMID PROJECT. PIE13/00041. Coordinated project. ISCIII. 2014-2016.
Daudén Tello, Esteban. INNPACTO. Estudio de biomarcadores en psoriasis. 2013-2015.
Daudén Tello, Esteban. Identificación de microRNAs como biomarcadores de gravedad y respuesta al tratamiento en pacientes con Psoriasis. PI14/01751. ISCIII. 2015-2017.
Daudén Tello, Esteban. Regulación de la expresión de CXCL12 y RAPTOR por miRNAs noveles y su papel en el proceso inflamatorio de la Psoriasis. PI17/01972. ISCIII. 2018-2020.
Determinar la importancia de los miRNAs en la inflamación característica de la psoriasis.
This grant is funded by the 2013-2016 Spanish Science, Technology and Innovation Research Plan and the ISCIII – Subdirectorate General for Evaluation and Promotion of Research – and co-financed by the European Regional Development Fund, Operational Programme Smart Growth 2014-2020 according to Regulation (EU) no. 1303/2013.
Naredo, Esperanza, Moeller, Ingrid, de Miguel, Eugenio, Batlle-Gualda, Enrique, Acebes, Carlos, Brito, Elia, Mayordomo, Lucia, Moragues, Carmen, Uson, Jacqueline, de Agustin, Juan J., Martinez, Agustin, Rejon, Eduardo, Rodriguez, Ana, Dauden, Esteban, Spanish Soc Rheumatology & Spanish, Ultrasound Sch. High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case-control study. Rheumatology (Oxford) 2011. 50: 1838-1848. FI: 4.058(Q2). PMID: 21700682. DOI: 10.1093/rheumatology/ker078.
de la Fuente H, Perez-Gala S, Bonay P, Cruz-Adalia A, Cibrian D, Sanchez-Cuellar S, Dauden E, Fresno M, García-Diez A, Sanchez-Madrid F. Psoriasis in humans is associated with down-regulation of galectins in dendritic cells. J Pathol 2012. 228: 193-203. FI: 7.585(Q1). PMID: 22271227. DOI: 10.1002/path.3996.
Julià A, Tortosa R, Hernanz JM, Cañete JD, Fonseca E, Ferrándiz C, Unamuno P, Puig L, Fernández-Sueiro JL, Sanmartí R, Rodríguez J, Gratacós J, Dauden E, Sánchez-Carazo JL, López-Estebaranz JL, Moreno-Ramírez D, Queiró R, Montilla C, Torre-Alonso JC, Pérez-Venegas JJ, Vanaclocha F, Herrera E, Muñoz-Fernández S, González C, Roig D, Erra A, Acosta I, Fernández-Nebro A, Zarco P, Alonso A, López-Lasanta M, García-Montero A, Gelpí JL, Absher D, Marsal S. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes. Hum. Mol. Genet. 2012. 21: 4549-4557. FI: 7.692(Q1). PMID: 22271227. DOI: 10.1002/path.3996.
Gallo E, Cabaleiro T, Román M, Solano-López G, Abad-Santos F, García-Díez A, Daudén E. The relationship between tumour necrosis factor (TNF)-alpha promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-alpha therapy in psoriasis: a case-control study. Br J Dermatol 2013. 169: 819-829. FI: 4.100(Q1). PMID: 23662788. DOI: 10.1111/bjd.12425.
Guinea-Viniegra J, Jiménez M, Schonthaler HB, Navarro R, Delgado Y, Concha-Garzón MJ, Tschachler E, Obad S, Daudén E, Wagner EF. Targeting miR-21 to Treat Psoriasis. Sci. Transl. Med. 2014. . FI: 15.843(Q1). PMID: 24574341. DOI: 10.1126/scitranslmed.3008089.
